Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial

Obstetrics and Gynecology

Volumn 107, Issue 1, 2006, Pages 18-27

  Mao, Constance ^a   Koutsky, Laura A ^b   Ault, Kevin A ^b   Wheeler, Cosette M ^b   Brown, Darron R ^b   Wiley, Dorothy J ^b   Alvarez, Frances B ^b   Bautista, Oliver M ^b   Jansen, Kathrin U ^b   Barr, Eliav ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VACCINE; VIRUS DNA; VIRUS VACCINE; PAPILLOMA VIRUS VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CANCER RISK; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG STABILITY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS PARTICLE; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; METHODOLOGY; PAPILLOMA VIRUS; REFERENCE VALUE; RISK ASSESSMENT; TIME; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REFERENCE VALUES; RISK ASSESSMENT; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 33644849136     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000192397.41191.fb     Document Type: Article

References (17)

1. Clifford GM, Smith JS, Plummer M, Munoz N, and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide a meta-analysis. Br J Cancer 2003;88:63-73.
2. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:11-9.
3. American Cancer Society. Cancer Facts and Figures 2004. Available at: http://www.cancer.org/downloads/STT/CAFF_ finalPWSecured.pdf. Retrieved November 4, 2005.
4. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
5. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-65.
6. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
7. Pratt D, Goldenthal K, Gerber A. Preventative human papillomavirus (HPV) vaccines: regulatory briefing document on endpoints. Vaccines and Related Biological Products Advisory Committee Meeting, November 28-29, 2001. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3805b1_01. htm. Retrieved November 4, 2005.
8. Broder S. From the National Institutes of Health. JAMA 1992;267:1892.
9. Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 2004;22:2936-42.
10. Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 2001;19:3733-43.
11. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-1 virus-like particles expressed in yeast. J Infect Dis 1997;176:1141-5.
12. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Comm Stat Theory Meth 1998;27:1305-22.
13. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicenter phase II efficacy trial. Lancet Oncol 2005;6:271-8.
14. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
15. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer; a meta-analysis. Br J Cancer 2003;89:101-105.
16. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographical region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
17. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84:394-8.